White label – Pompe disease - ClinicalTrials.eu

Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease

Not recruiting

2 1
Investigated Diseases:
- Multiple system atrophy
- Parkinson’s disease
Investigated Drugs:
- Exidavnemab
Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

Not recruiting

3 1 1
Investigated Diseases:
- Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency
Investigated Drugs:
- Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Not recruiting

3 1 1 1
Investigated Diseases:
- Oesophageal adenocarcinoma
- Gastric cancer
Investigated Drugs:
+6
Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

Not recruiting

2 1 1 1
Investigated Diseases:
- Follicular lymphoma
- Diffuse large B-cell lymphoma
Investigated Drugs:
Trial of Ataluren for Severe Common Variable Immunodeficiency with Autoimmunity in Patients with LRBA Deficiency

Not recruiting

2 1 1 1
Investigated Drugs:
- Ataluren
Study of NIDO-361 for Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Not recruiting

2 1
Investigated Diseases:
- Bulbospinal muscular atrophy congenital
Investigated Drugs:
- Nido-361
Study on Bepranemab for Patients with Early Alzheimer’s Disease

Not recruiting

2 1 1
Investigated Drugs:
+1
Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

Not recruiting

3 1 1
Investigated Diseases:
- Factor IX deficiency
- Factor VIII deficiency
Investigated Drugs:
- Concizumab
+5
Study Comparing Abemaciclib and Fulvestrant with Placebo and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer After Previous Treatment

Not recruiting

3 1 1
Investigated Diseases:
- Breast neoplasm
Investigated Drugs:
- Abemaciclib
- Fulvestrant
+3
Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Not recruiting

3 1 1 1
Investigated Drugs:
+9

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies